Log in or register to see all Alerts
New HTA Decisions in England
June 2020
Drug name
SOLIRIS® (eculizumab)
Company
Alexion Pharma UK
Decision date
30/06/2020
Therapeutic area
Neurological conditions
Therapeutic sub area
Neurological conditions: general and other
Decision
Recommended
Indication
Refractory myasthenia gravis.
Decision Detail
This was a terminated appraisal.
Summary
NICE was unable to make a recommendation on eculizumab (Soliris) for treating refractory myasthenia gravis because the company did not provide an evidence submission. NICE will review this decision if the company decides to make a submission.